Journal article
Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer
Abstract
PURPOSE: We have observed cavitation of lesions in clinical trials of an angiogenesis inhibitor combined with chemotherapy for non-small-cell lung cancer (NSCLC). We hypothesized that cavitation might alter response assessment in such clinical trials.
PATIENTS AND METHODS: We performed a retrospective radiologic review of patients with NSCLC enrolled onto three National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trials of …
Authors
Crabb SJ; Patsios D; Sauerbrei E; Ellis PM; Arnold A; Goss G; Leighl NB; Shepherd FA; Powers J; Seymour L
Journal
Journal of Clinical Oncology, Vol. 27, No. 3, pp. 404–410
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 20, 2009
DOI
10.1200/jco.2008.16.2545
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAngiogenesis InhibitorsAntimetabolites, AntineoplasticAntineoplastic Agents, PhytogenicCarboplatinCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineFemaleHumansLung NeoplasmsMaleMiddle AgedOutcome and Process Assessment, Health CarePaclitaxelRadiographyRetrospective StudiesVascular Endothelial Growth Factor AGemcitabine